Skip to main content

The importance of good nutrition

A chronic condition

Type 2 diabetes has emerged as a significant chronic condition in Australia, and many other developed nations.

With a low Glycemic Index (GI), and low Glycemic Load (GL), BARLEYMAX® wholegrain has two of the key properties for the management and prevention of type 2 diabetes.

I think it’s a wonderful product for health and started eating when blood sugar was getting high.

Wendy MQLD
Diabetes - A woman test her insulin levels
BarleyMAX - Resistant starch and insulin sensitivity

Resistant starch and insulin sensitivity

Increasing your wholegrain consumption has been shown to reduce the risk of type 2 diabetes by 20-30%.

BARLEYMAX® not only features significantly lower GI and GL than standard barley, it also has high levels of resistant starch. Resistant starch helps to maintain blood sugar levels by increasing the body’s sensitivity to insulin.

Glycemic index

Diet management, in particular the management of Glycemic Index (GI) and Glycemic Load (GL), is recognised as key to both the management and prevention of type 2 diabetes.

Studies have shown that diets that have a high glycemic load are associated with an increased risk of developing type 2 diabetes, cardiovascular disease and certain cancers.1

Diabetes - BARLEYMAX graph GI comparison

Lower GI than regular barley

According to a 2002 study2, choosing low-GI foods in place of conventional or high-GI foods has a useful effect on medium-term glycemic control in patients with type 2 diabetes. The benefits of low-GI foods are similar to those offered by pharmacological agents that also target postprandial hyperglycemia.

A recent study that compared breakfast cereal made with BARLEYMAX® to standard barley, showed a significantly lower rise in blood insulin levels.

BARLEYMAX® Fact

Choosing low-GI foods in place of conventional or high-GI foods has a small but clinically useful effect on medium-term glycemic control in patients with type 2 diabetes. The incremental benefit is similar to that offered by pharmacological agents that also target postprandial hyperglycemia.

Request a sample